---
title: Vusolimogene oderparepvec
slug: vusolimogene-oderparepvec
qid: 
snapshot: enwiki-001376991482
content_hash: 
license: CC BY-SA 4.0
source: https://en.wikipedia.org/w/index.php?oldid=1376991482
tags: [106462793, 106462794, 106762838, 108130626, 126681261, 23603337, 23617853, 26974467, 27236659, 27717831, 30445162, 32308905, 50769796, 61955657, 63007578, 68150358, 68328988, 84215243]
---

# Vusolimogene oderparepvec

> [!note] Provenance
> Snapshot `enwiki-001376991482` · content root `…`
> Derived from <https://en.wikipedia.org/w/index.php?oldid=1376991482> · Licensed CC BY-SA 4.0

Vusolimogene oderparepvec, sold under the brand name Tudriqev, is an anti-cancer medication used for the treatment of melanoma. It is a genetically modified herpes simplex virus type 1 oncolytic virus that is injected directly into tumors. The most common non-laboratory adverse reactions include fatigue, pyrexia, infections, chills, musculoskeletal pain, nausea, diarrhea, injection site reaction, headache, cough, influenza like illness, rash, vomiting, pruritus, arthralgia, constipation, decreased appetite, dizziness, dyspnea, hemorrhage, edema, and abdominal pain. Vusolimogene oderparepvec was approved for medical use in the United States in August 2026.

Vusolimogene oderparepvec, sold under the brand name Tudriqev, is an anti-cancer medication used for the treatment of melanoma. It is a genetically modified herpes simplex virus type 1 oncolytic virus that is injected directly into tumors. The most common non-laboratory adverse reactions include fatigue, pyrexia, infections, chills, musculoskeletal pain, nausea, diarrhea, injection site reaction, headache, cough, influenza like illness, rash, vomiting, pruritus, arthralgia, constipation, decreased appetite, dizziness, dyspnea, hemorrhage, edema, and abdominal pain. Vusolimogene oderparepvec was approved for medical use in the United States in August 2026.
